Table 4. Correlation between preoperative basic patient information and partial pathological response.

Parameters	MPR (N=16)	Non-MPR (N=22)	P value
Age
Mean ± SD	64.75 (3.60)	59.55 (1.40)	0.019 [1]*
Gender
Male	15	21	1.000 [2]
Female	1	1
Smoking history
Yes	7	15	0.132 [3]
No	9	7
Drinking history
Yes	6	11	0.444 [3]
No	10	11
BMI
<18.5	1	2	1.000 [2]
≥18.5	15	20
Tumour location
Proximal third	0	3	0.240 [2]
Middle third	11	10
Distal third	5	9
Interval from completion of NACI to surgery (weeks)	4.94(0.98)	6.27(0.61)	0.199 [1]
Neoadjuvant therapy regimens
Cis-platinum + Paclitaxel + Camrelizumab	4	4	0.341 [2]
Carboplatin + Paclitaxel + Camrelizumab	1	3
Cis-platinum + Paclitaxel + Pembrolizumab	6	10
Cis-platinum + Paclitaxel + Sintilimab	3	0
Carboplatin + Paclitaxel + Pembrolizumab	2	3
Paclitaxel + Nedaplatin + Sintilimab	0	2
Chemotherapy course + immunotherapy course
<4	2	4	1.000 [2]
≥4	14	18
Immunotherapy regimen
Camrelizumab	5	7	0.732 [2]
Pembrolizumab	8	13
Sintilimab	3	2
Immunotherapy course
<2	2	3	1.000 [2]
≥2	14	19
Staging
III	12	19	0.425 [2]
IVA	4	3

[1]: P value is calculated by t-test; [2]: P value is calculated by Fisher exact test; [3]: P value is calculated by chi-squared test. Main Pathological Reaction, MPR; P>0.05 NS, *P<0.05.